JP2020523381A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523381A5
JP2020523381A5 JP2019569336A JP2019569336A JP2020523381A5 JP 2020523381 A5 JP2020523381 A5 JP 2020523381A5 JP 2019569336 A JP2019569336 A JP 2019569336A JP 2019569336 A JP2019569336 A JP 2019569336A JP 2020523381 A5 JP2020523381 A5 JP 2020523381A5
Authority
JP
Japan
Prior art keywords
compound
formula
protecting group
nuc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523381A (ja
JP7248209B2 (ja
Filing date
Publication date
Priority claimed from GBGB1709471.5A external-priority patent/GB201709471D0/en
Application filed filed Critical
Publication of JP2020523381A publication Critical patent/JP2020523381A/ja
Publication of JP2020523381A5 publication Critical patent/JP2020523381A5/ja
Application granted granted Critical
Publication of JP7248209B2 publication Critical patent/JP7248209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569336A 2017-06-14 2018-06-14 3’-デオキシアデノシン-5’-o-[フェニル(ベンジルオシキ-l-アラニニル)]ホスフェート(nuc-7738)の合成 Active JP7248209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709471.5A GB201709471D0 (en) 2017-06-14 2017-06-14 Diastereoselective synthesis of hosphate derivatives
GB1709471.5 2017-06-14
PCT/GB2018/051641 WO2018229495A1 (en) 2017-06-14 2018-06-14 Synthesis of 3'-deoxyadenosine-5'-0-[phenyl(benzyloxy-l-alaninyl)]phosphate (nuc-7738)

Publications (3)

Publication Number Publication Date
JP2020523381A JP2020523381A (ja) 2020-08-06
JP2020523381A5 true JP2020523381A5 (enExample) 2021-07-26
JP7248209B2 JP7248209B2 (ja) 2023-03-29

Family

ID=59358400

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019569286A Active JP7279991B2 (ja) 2017-06-14 2018-06-14 ホスフェート誘導体の合成
JP2019569336A Active JP7248209B2 (ja) 2017-06-14 2018-06-14 3’-デオキシアデノシン-5’-o-[フェニル(ベンジルオシキ-l-アラニニル)]ホスフェート(nuc-7738)の合成
JP2023076006A Active JP7525687B2 (ja) 2017-06-14 2023-05-02 ホスフェート誘導体の合成
JP2024114519A Pending JP2024138523A (ja) 2017-06-14 2024-07-18 ホスフェート誘導体の合成
JP2025266864A Pending JP2026034703A (ja) 2017-06-14 2025-12-19 ホスフェート誘導体の合成

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019569286A Active JP7279991B2 (ja) 2017-06-14 2018-06-14 ホスフェート誘導体の合成

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023076006A Active JP7525687B2 (ja) 2017-06-14 2023-05-02 ホスフェート誘導体の合成
JP2024114519A Pending JP2024138523A (ja) 2017-06-14 2024-07-18 ホスフェート誘導体の合成
JP2025266864A Pending JP2026034703A (ja) 2017-06-14 2025-12-19 ホスフェート誘導体の合成

Country Status (18)

Country Link
US (4) US11897913B2 (enExample)
EP (2) EP3638684A2 (enExample)
JP (5) JP7279991B2 (enExample)
KR (2) KR102920287B1 (enExample)
CN (3) CN110785425B (enExample)
AU (3) AU2018284131B2 (enExample)
BR (1) BR112019026747A2 (enExample)
CA (2) CA3065682A1 (enExample)
CL (1) CL2019003632A1 (enExample)
EA (1) EA201992873A1 (enExample)
GB (1) GB201709471D0 (enExample)
IL (3) IL302559B2 (enExample)
MA (1) MA49379A (enExample)
MX (3) MX390901B (enExample)
PH (1) PH12019502825A1 (enExample)
SA (1) SA519410795B1 (enExample)
SG (1) SG11201911543UA (enExample)
WO (2) WO2018229495A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3039965T3 (en) 2011-03-01 2025-10-28 NuCana plc Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
PT3119794T (pt) 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
SG10202009020VA (en) * 2014-11-28 2020-10-29 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN112409421A (zh) * 2020-12-01 2021-02-26 上海兆维科技发展有限公司 一种3’-磷酸酯核苷的制备方法
IL316821A (en) 2022-05-12 2025-01-01 NuCana plc Cancer treatment with NUC-7738
CN120584123A (zh) 2022-12-07 2025-09-02 努卡那有限公司 核苷衍生物nuc-3373的合成

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279248C (enExample)
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006063149A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090206007A1 (en) 2008-02-20 2009-08-20 Air Products And Chemicals, Inc. Process and apparatus for upgrading coal using supercritical water
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
MX2011009728A (es) 2009-03-20 2011-10-14 Alios Biopharma Inc Analogos nucleotido y nucleosido sustituidos.
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
ES3039965T3 (en) 2011-03-01 2025-10-28 NuCana plc Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
WO2014033617A1 (en) 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CZ307789B6 (cs) * 2014-04-15 2019-05-09 Zentiva, K.S. Způsob výroby biologicky účinných fosforamidátových léčiv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
PT3119794T (pt) 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
ES2927212T3 (es) 2014-08-25 2022-11-03 Medivir Ab Análogos de dioxano de uridina para el tratamiento de cáncer
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
SG10202009020VA (en) 2014-11-28 2020-10-29 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
WO2016098123A2 (en) * 2014-12-16 2016-06-23 Laurus Labs Private Ltd A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CA2985540C (en) 2015-05-14 2021-08-24 NuCana plc Use of nuc-1031 in the treatment of cancer
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
US10745435B2 (en) * 2015-11-16 2020-08-18 Cerecor, Inc. Nucleic acid prodrugs
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
EP3393478B1 (en) 2015-12-23 2020-03-04 NuCana plc Combination therapy
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens

Similar Documents

Publication Publication Date Title
JP2020523381A5 (enExample)
JP6634135B2 (ja) ハリコンドリンb類縁体の合成に有用な方法
DE69428280T2 (de) Verfahren zur herstellung von azetidinonen
JP2022043078A5 (enExample)
JP2006510719A5 (enExample)
JP2020523378A5 (enExample)
JP2022031717A5 (enExample)
JP2019048806A5 (enExample)
JP2014500870A5 (enExample)
CN104262344A (zh) 艾德拉尼的制备方法
IS2060B (is) Aðferð til framleiðslu á hreinu sítalóprami
JP2019529549A5 (enExample)
NO20070865L (no) Fremgangsmate for fremstilling av 2'-deoksy-2',2'-difluorcytidin.
FI3529234T3 (fi) Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon
JP6736317B2 (ja) ロタキサン化合物
JP2004531527A5 (enExample)
JP2011526896A5 (enExample)
JP2021503522A5 (enExample)
WO2020010560A1 (zh) 一种亚磷酰胺类化合物、其制备方法及应用
CN108948066A (zh) 一种艾日布林中间体的制备方法
JP2005536559A5 (enExample)
JP4373342B2 (ja) スピロフルオレノールの製造方法
CA2281104A1 (en) Selective epoxidation process for preparing pharmaceutical compounds
WO2007049295B1 (en) An improved one pot process for making key intermediate for gemcitabine hcl
CN105384668A (zh) 用于制备醚化合物的方法